We all wanted to run the full distance and were aware that we needed a lot of perseverance and sufficient reserves on the last few miles to reach the goal.
Karlheinz Schmelig
Managing Partner Creathor Ventures

“The trade sale of Sividon to Myriad was the result of some kind of a marathon run consisting of years of negotiations and two M & A processes at the end of which the selling price was more than 100 percent above the first offer.”
Creathor Venture’s Managing Partner Karlheinz Schmelig writes about the long Sividon exit in Ernst & Young’s annual German biotech report “Spot on Innovation!”.

Please follow this link to read the full article in German on page 70.